{"id":"W2992194132","doi":"10.1007/s12079-019-00542-6","title":"Breathe, breathe in the air: the anti-CCN2 antibody pamrevlumab (FG-3019) completes a successful phase II clinical trial for idiopathic pulmonary fibrosis","year":2019,"lang":"en","type":"article","venue":"Journal of Cell Communication and Signaling","topic":"Connective Tissue Growth Factor Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":13,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Nintedanib; Pirfenidone; Medicine; Idiopathic pulmonary fibrosis; Tolerability; Clinical trial; Vital capacity; Internal medicine; Intensive care medicine; Lung; Adverse effect; Diffusing capacity; Lung function","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004401266,0.0001386224,0.0003249607,0.00007265498,0.0003016451,0.00007456364,0.0008884784,0.0001204817,0.00001831655],"category_scores_gemma":[0.0002592717,0.00008477543,0.0002474356,0.0001278963,0.0001481251,0.00001988221,0.0002227667,0.0004686608,0.000001585727],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001342518,"about_ca_system_score_gemma":0.0001076199,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001814926,"about_ca_topic_score_gemma":0.000009214968,"domain_scores_codex":[0.9974933,0.001186028,0.0007015821,0.0001794119,0.0002416808,0.0001980345],"domain_scores_gemma":[0.9977441,0.0009184422,0.0004449857,0.0005795075,0.0002565314,0.00005641507],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.01114216,0.001486563,0.01411514,0.00009449225,0.0001213166,0.000006264144,0.00112497,0.00004713526,0.9649686,0.0001385162,0.0001666154,0.006588229],"study_design_scores_gemma":[0.3312576,0.04871026,0.0583316,0.001848884,0.0008471667,0.001129834,0.01671882,0.01266062,0.3744029,0.004126372,0.1476604,0.002305551],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9921595,0.0051054,0.0003900268,0.001358956,0.00006915127,0.0007023867,0.00001394448,0.000002885074,0.0001976929],"genre_scores_gemma":[0.9977992,0.001518613,0.0001681311,0.0001964113,0.0002122602,0.00001497015,0.00002834804,0.00001669173,0.00004534811],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5905657,"threshold_uncertainty_score":0.3457042,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05069009097817694,"score_gpt":0.3877615938795685,"score_spread":0.3370715029013916,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}